HIV-2: Clinical Features, Diagnosis, and Management
Overview
No CME Credit Available
Level: Advanced
Release Date: March 31, 2016
Date of Last Review/Update: February 11, 2019
Expiration Date: February 11, 2020
This Cases on the Web (COW) activity introduces a case and presents clinical decision points, each focusing on the clinical management of a woman diagnosed with HIV-2 infection.
At each decision point, participants should select the option that they think is most sound and then read the presenters’ explanation of that option. Selecting the correct option links the participant to an extended discussion of the related medical findings, research-based evidence, and case-management considerations.
To advance from one clinical decision point to the next, participants should click on the NEXT button located at the bottom of the page that discusses the best clinical option.
After reviewing the cases, participants may access the activity posttest and the course evaluation, both of which must be completed and submitted to claim continuing medical education (CME) credit, a certificate of participation, continuing education units (CEUs), or pharmacy credits. Please see the posttest form and course evaluation form for further instructions.
You may sample the activity without logging in by clicking the links in the sidebar. You must be logged in the entire time in order to claim CME credit for the activity.
Learning Objectives
On completion of this activity, learners will be able to:
- Identify patients who are at risk of HIV-2 infection, based on epidemiologic characteristics
- Compare the transmissibility and natural history of HIV-2 to that of HIV-1
- Describe when to initiate antiretroviral therapy and which initial regimen to choose for patients with HIV-2 infection
- Monitor patients with HIV-2 infection who are taking antiretroviral therapy
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians on the evolving challenges of managing HIV disease. This activity examines the clinical features, diagnosis, and management of HIV-2 disease.
Intended Audience
This enduring material is designed for physicians who are actively treating or will be treating patients with HIV infection.
This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.
CME Information
Accreditation
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
The IAS–USA designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is offered from February 11, 2019 to February 11, 2020. Physicians (MDs, DOs, and international equivalents) who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Other health care practitioners will receive a Certificate of Participation.
Nursing Continuing Education Contact Hours
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.25 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Program expires February 11, 2020.
Pharmacy Continuing Education Contact Hours
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.25 hours (0.125 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
UAN # 0761-9999-19-041-H02-P
Program expires February 11, 2020
Faculty
Authors
Jacqueline T. Chu, MD
Dr Chu is the HIV Program Director at the Chelsea HealthCare Center of Massachusetts General Hospital (MGH) in Chelsea, Massachusetts. She practices infectious disease (ID) medicine and HIV primary care both at Chelsea and at MGH in Boston. She is an Instructor of Medicine at Harvard Medical School (HMS) and the faculty director of the HMS ID Student Interest Group.
Rajesh T. Gandhi, MD
Dr Gandhi is Director of HIV Clinical Services and Education at Massachusetts General Hospital (MGH), site leader of the MGH Clinical Research Site in the AIDS Clinical Trials Group, Director of the Harvard University Center for AIDS Research Clinical Core, and Professor of Medicine at Harvard Medical School in Boston, Massachusetts
Editor
Marshall J. Glesby, MD, PhD
Dr Glesby is Professor of Medicine and Associate Chief of the Division of Infectious Diseases at Weill Cornell Medical College, Medical Director of the Cornell HIV Clinical Trials Unit, and Regional Clinical Director of the New York–Northeast Caribbean AIDS Education and Training Center in New York, New York.
Disclosure of Financial Interests
It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty members (planners, speakers, presenters, etc) participating in IAS–USA-sponsored activities are required to disclose to the program audience any financial relationships with commercial interests within the past 12 months that could be perceived to influence, or give the appearance of potentially influencing, the written or oral presentation. The Accreditation Council for Continuing Medical Education (ACCME) defines a financial interest as an interest in any amount and defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.” The information is intended to make the IAS–USA audience aware of speaker and contributor interests and commitments with commercial interests, enabling the audience members to form their own judgments about such associations.
Each author or contributor is required to complete this financial disclosure declaration. In accordance with IAS–USA policy, the IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Financial relationship information about authors and editor is included here; information on the Cases on the Web Editorial Board can be found at https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/.
Faculty
Dr Chu has received research grants to her institution from Janssen Therapeutics, ViiV Healthcare, and Gilead Sciences, Inc, and has interest through a brokerage in Johnson & Johnson and Pfizer. (Updated 02/04/19)
Dr Gandhi has served as a consultant or advisor to Merck and Gilead Sciences, Inc, and received educational and research grants to his institution from ViiV Healthcare, Janssen Therapeutics, Theratechnologies, and Gilead Sciences, Inc. (Updated 01/31/19)
Editor
Dr Glesby has received research support paid to his institution from Gilead Sciences, Inc. (Updated 09/10/18)
Grant Support
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
2019 Grant Support
For our HIV effort:
Platinum Supporters
Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare
Additional Supporter
Janssen Therapeutics
Cases on the Web Editorial Board
Members of the COW Editorial Board participate in a volunteer capacity. They are not compensated for their role in overseeing the program. Listed below are the COW Editorial Board members and their financial interests with commercial companies within the past 12 months from the date of disclosure. Click here to view the COW Editorial Board.
Drug and Product Disclaimer
This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this COW activity.
The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the IAS–USA.
Contact Information
If you have any questions about this COW activity, please contact the IAS–USA:
IAS–USA
131 Steuart St
Ste 500
San Francisco, CA 94105
Telephone: (415) 544-9400
Email: info@iasusa.org